A cewar wani binciken da aka buga a cikin New England Journal of Medicine da aka buga a ranar 5 ga Yuli, gabaɗayan Cabozantinib da rayuwa ba tare da ci gaba ba a cikin marasa lafiya tare da ci-gaban ciwon hanta ya kasance mafi kyau fiye da rukunin placebo.
Dokta Ghassan K. Abou-Alfa daga Cibiyar Ciwon Kankara ta Memorial Sloan a Birnin New York da abokan aiki sun ba da izini ga marasa lafiya 707 tare da ci gaba da ciwon hanta don karɓar carbotinib ko madaidaicin placebo a cikin rabo na 2 zuwa 1. Mahalarta sun sami magani na sorafenib kuma suna da ci gaban cuta bayan daya ko fiye da tsarin jiyya na ciwon hanta.
A cikin tsaka-tsakin bincike na shiri na biyu, fitinar ta nuna cewa rayuwar carbotinib gaba daya ta fi ta placebo muhimmanci.
Masu binciken sun gano cewa matsakaiciyar rayuwar carbotinib da placebo sun kasance watanni 10.2 da 8.0, bi da bi (yanayin haɗari na mutuwa ya kasance 0.76). Don carbotinib da placebo, rashin samun ci gaba na tsakiya ya kasance watanni 5.2 da 1.9, bi da bi. 68% da 36% na marasa lafiya a cikin rukunin carbotinib da rukuni na placebo sun sami ƙwarewar 3 ko 4 abubuwan da suka faru, bi da bi. Abubuwan da aka fi sani da manyan-manyan lamura sune na dabino da ake kira erythema, jin hawan jini, hawan matakan aspartate aminotransferase, gajiya da gudawa, wadanda duk sun fi yawa da carbatinib.
Marubutan sun rubuta cewa, "A cikin marasa lafiya da ke fama da cutar sanyin hanta a baya, magani tare da carbotinib na iya haifar da rayuwa gaba daya da rashin ci gaba fiye da placebo."
https://www.drugs.com/news/cabozantinib-improves-survival-advanced-hepatocellular-cancer-75490.html
